Active Hexose Correlated Compound (AHCC) has been the subject of more than 20 human and animal studies, and researchers found that AHCC is beneficial to treat cancers due to its antitumor properties.
These Shiitake mushrooms extract have been known for centuries for their healing properties in Asian medicine, whereby AHCC is used in over 700 clinics and hospitals in Japan, mainly used against most tumors in cancer treatment.
According to Journal of Clinical Oncology, a nationwide survey on Complementary and Alternative Medicine (CAM) in Japan revealed a high prevalence of CAM use among cancer patients:
- The prevalence of CAM use was 44.6% (1,382 of 3,100) in cancer patients, and 25.5% (92 of 361) in noncancer patients with benign tumors.
- Most CAM users with cancer (96.2%) used products such as mushrooms and herbs.
We look into the medical study, clinical results, and AHCC supplement user reviews on the use of AHCC as complementary and alternative medicine (CAM) in cancer treatment. For instance:
AHCC Cancer Research: Tumor Surveillance Enhancement
Source:
Yale School of Medicine, New Haven, USA.
Topic:
AHCC enhances tumor surveillance through regulating both innate and adaptive immune responses
Abstract:
AHCC has been implicated to modulate immune functions and plays a protective role against infection. In this study, C57BL/6 mice were orally administered AHCC or water, followed by tumor cell inoculation, shown in comparison to pure water-treated mice.
Results / Conclusion:
Results demonstrated that AHCC treatment significantly delayed tumor development, and AHCC can enhance tumor immune surveillance through regulating both innate and adaptive immune responses.
Click To Learn More Specifically On Each Cancer Treatment, AHCC Medical / Clinical Results, AHCC dosage for cancer treatment, and AHCC Cancer Patients’ Testimonials / Experiences:
- AHCC Breast Cancer
- AHCC Cervical Cancer
- AHCC Chemotherapy
- AHCC Colon Cancer
- AHCC Liver Cancer
- AHCC Lung Cancer
- AHCC Ovarian Cancer
- AHCC Prostate Cancer
Dr. Geovanni Espinosa, Director of the Integrative Urological Center at New York University Langone Medical Center, further discusses AHCC and its use in cancer patients in brief video below.